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INTRODUCTION:  Primary  neuroendocrine  breast  carcinoma  (NEBC)  is a  rare entity  of breast  cancer.
PRESENTATION  OF  CASE:  We  herein  report  a  case  of  right hepatectomy  for a NEBC  liver metastasis.
DISCUSSION:  Little  is known  about  its evolution,  bilologic  behavior  and  optimal  treatment.  Its  malignant
potential  has been  addressed  in  few  reports,  with  cases  of metachronous  metastases  in  diverse sites,  even
years  following  treatment  of the  breast  primarily.eywords:
reast cancer
euroendocrine breast carcinoma
iver metastasis
CONCLUSION:  Treating  this  kind  of  cancer  implies  both  breast  and  hepatic  surgery.
Primary  neuroendocrine  breast  carcinoma  (NEBC)  is a rare  entity  of  breast  cancer.  Little  is known  about
its evolution,  biologic  behavior  and  optimal  treatment.  Its  malignant  potential  has  been  addressed  in  few
reports,  with  cases  of  metachronous  metastases  in  diverse  sites,  even  years  following  treatment  of  the
breast  primarily.  We  herein  report  a case  of  right  hepatectomy  for a NEBC  liver  metastasis.
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. Introduction
Primary neuroendocrine breast carcinoma was ﬁrst described
y Cubilla and Woodruff.1 Several reports deﬁned the com-
on  features of NEBCs according to macroscopic, histological
nd immunohistochemical ﬁndings.2,3 However, due to lack of
nambiguous diagnostic criteria, the actual incidence remained
nknown. According to the most recent World Health Organi-
ation (WHO) classiﬁcation of breast and gynecologic tumors,4
heir incidence is estimated, approximately, to 1% of all breast
arcinomas.
. Case report
A 51-year-old Caucasian female presented with a multilobu-
ated 8.4 cm mass lesion in the liver (segment VII). The lesion was
iscovered in the context of follow up of surgically excised breast
arcinoma of neuroendocrine differentiation (NEBC) 8 years ago.
t that time she had undergone quandrantectomy of the left breast
nd ipsilateral axillary lymph node dissection. The primary tumor
as an invasive low-grade (Grade III), T2N0M0 adenocarcinoma of
euroendocrine differentiation, with positive estrogen receptors,
egative progesterone receptors and negative c-erb-B2. Initially,
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the patient was  treated with 6 cycles of chemotherapy consisting
of cyclophosphamide-epirubicin-5FU and local radiotherapy, fol-
lowed by endocrine therapy of 3 years tamoxifen switched to 2
years aromatase inhibitor (AI) and LH-RH analogue.
A multidimensional computed tomography (MDCT) of the
abdomen was  undertaken in the course of the annual follow-up,
8 years after the initial surgical treatment. A metastatic lesion in
the right liver, invading segments VI and VII was revealed and
conﬁrmed through an abnominal MRI  with iv contrast (Fig. 1a).
The preoperative tumor markers CA-125, CA15-3 and CA19-9 were
within normal ranges. The patient underwent a right hepatectomy
and the histologic examination conﬁrmed its neuroendocrine ori-
gin, exhibiting morphological similarities to the breast primary
tumor. In particular, the histological picture was compatible with
a large cell, grade 3 neuroendocrine carcinoma (Figs. 2–4). The
tumor showed moderate cellular atypia, increased mitotic ﬁgures
(>16/100 visual ﬁelds), foci of necrosis, as well as neoplastic vas-
cular emboli inside the main tumor mass. Satellite lesions were
presented close to the main liver mass, invading the portal tracts.
Tumor cells were NSE (++), synaptophysin (++), CD56(++), chro-
mogranin (+), CK(++), ER(+), PR(−), cerbB2(−), HepPar-1(−), and
TTF1(−). The residual non neoplastic hepatic parenchyma showed
focal mild sinusoidal dilatation, with mild focal cholestasis, mod-
erate ﬁbrosis and chronic inﬂammatory cellular inﬁltration of
the portal tracts. Both histology and immunohistochemistry indi-
cated that the liver mass represented a metastasis of the known
breast carcinoma. The patient remains free of disease, 18 months
postoperatively (Fig. 1b).
s Ltd. This is an open access article under the CC BY-NC-ND license
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Fig. 1. (a) MRI  abdomen–pelvis. (b) Post resection MRI.
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Fig. 3. Tumor cells are positive to NSE.
neuroendocrine component and the degree of its differentiation.ig. 2. Liver tumor with neuroendocrine differentiation and comedo-like necrosis,
ematoxylin–Eosin staining.
. Discussion
The existence of neuroendocrine cells in normal breast epithe-
ium is controversial.5–8 Since no hyperplastic or benign neoplastic
euroendocrine cell proliferations have been recorded in the
reast, it has been suggested that NEBCs result from a divergentFig. 4. Tumor cells are positive to synaptophysin.
differentiation event in breast cancer.9 The presence of an in situ
component with NE characteristics, further supports this notion,
suggesting possible progression to invasive forms.10 The in situ
component along with the imaging modalities (excluding a non-
mammary site) will further establish the primary nature of the
NEBC.
The diagnosis of NEBC relies on the presence of morphologic
neuroendocrine features and neuroendocrine markers expressed
in more than 50% of tumor cells.4 The most sensitive and speciﬁc
NE markers, are chromogranin A and B and synaptophysin. Accord-
ing to the above criteria, NEBCs constitute approximately 1% of all
breast carcinomas. In 2012, the last edition of World Health Orga-
nization (WHO) classiﬁcation of breast and gynecologic tumors,
described 4 main histologic types: solid (usually of low to inter-
mediate grade), small/oat cell and large cell, that are both poorly
differentiated variants and lately added atypical carcinoid tumor.11
In terms of prognostic and predictive factors, HER-2 is almost
always absent in NEBCs, while the vast majority express estro-
gen and/or progesterone receptors. The prognostic relevance of
neuroendocrine differentiation is controversial,12,13 though most
studies report a relatively poor prognosis based on the extent of theIn the literature, there have been reports about NEBCs metas-
tasizing to multiple sites, even years following treatment of the
primary breast tumor and despite the administration of systemic
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eports of neuroendocrine breast carcinoma metastases.
Author Site of metastasis from NEBC
Imamura et al.14 Liver
Shimizu et al.15 Stomach
Rischke et al.16 Liver
Loo et al.17 Thyroid, bone
Berruti et al.18 Lungs
Hennessy et al.19 Perianal, bone, liver, heart
McIntire et al.20 Liver, pancreas
Ulamec et al.21 Renal cell carcinoma, adrenal gland
Suchak et al.22 Pleural tissue
Hassani et al.23 Brain
Yamaguchi et al.24 Pelvic bone
Okines et al.25 Sacral bone
Buttar et al.26 Brain, pancreas, lungs, liver, bones
herapy.14–26 Although there are only case reports of NEBCs metas-
ases, the diversity of metastatic sites is unremarkable (Table 1),
hile there are scattered data regarding the treatment strategies.
mamura,14 has reported the curative resection of multiple hepatic
etastases by means of a lateral segmentectomy of the liver.
n other reports, an alternative approach included Transcatheter
rterial Chemoembolization (TACE) and octreotide administration,
long with resection of the breast primary was instituted.16 The
esponse to systemic therapy has been inconsistent with progres-
ion of the disease.17–19,22–24
Funding
There is no source of funding for our research.
Ethical approval
Written informed consent was  obtained from the patient for
publication of this case report and accompanying images. A copy
of the written consent is available for review by the Editor-in-Chief
of this journal on request.
Author contributions
Manes Konstantinos: conception and design, acquisition of data,
analysis and interpretation of data; drafting the article, critical revi-
sion of the article; ﬁnal approval of the version to be published. Delis
Spyridon: conception and design, acquisition of data, analysis and
interpretation of data; drafting the article, critical revision of the
article; ﬁnal approval of the version to be published. Papaspyrou
Nikolaos: acquisition of data, analysis and interpretation of data;
drafting the article; ﬁnal approval of the version to be published.
Ghiconti Ioanna: acquisition of data; critical revision of the article;
ﬁnal approval of the version to be published. Dervenis Christos:
conception and design; critical revision of the article; ﬁnal approval
of the version to be published.
Key learning points
• Neuroendocrine breast cancer, metastatic to the liver is a rare entity, with few reported cases in literature.
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1here is no widely accepted systemic therapy for NEBC for the
oment. Close follow-up of patients is mandatory, since metas-
ases can appear late and in diverse sites. Howlader et al. performed
 review of the management of liver metastases from breast
arcinoma and proposed a management guideline, based on the
act that prolonged survival can be obtained after hepatectomy.27
iver surgery is recommended, in absence of extrahepatic disease
except for bone metastases which are easily controlled by radio-
herapy or isolated pulmonary metastasis) if an R0 resection is
easible with accepted mortality.
Our patient developed a delayed solitary liver metastasis from
EBC. In face of lack of efﬁcient systemic therapy and according
o the established international practice of resection of neu-
oendocrine hepatic metastases, a more aggressive approach was
ustiﬁed. In addition, the solitary site of the lesion may  explain such
ggressive approach. In such cases, a multidisciplinary approach
ncluding HPB surgeons, is strongly recommended.
A large, 86.9 mm × 72.9 mm,  multilobulated, space occupying
esion is detected in the hepatic segment VII. The lesion presents
ith inhomogeneous intermediate signal intensity (higher than
hat of the surrounding liver parenchyma) in T2 weighted and T2
eighted with fat saturation, sequences, as well as with an exten-
ive central area of higher signal intensity, which most probably
epresents central necrosis. After iv administration of paramagnetic
gent, the above mentioned lesion exhibits pronounced, inhomo-
eneous contrast enhancement with sparing of the central area.
• Metachronous metastases of such a carcinoma should b
• Treating this kind of cancer implies both breast and heponﬂict of interest
There is no conﬂict of interest by none of the authors.
1t in mind of the clinician.
surgery.
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